4//SEC Filing
Anish Bhatnagar 4
Accession 0001415889-25-009290
CIK 0001484565other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 7:00 PM ET
Size
51.5 KB
Accession
0001415889-25-009290
Insider Transaction Report
Form 4
Anish Bhatnagar
DirectorSee Remarks
Transactions
- Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−62,291→ 52,709 totalExercise: $2.41Exp: 2033-01-25→ Common Stock (62,291 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−281,053→ 200,753 totalExercise: $5.25Exp: 2033-05-26→ Common Stock (281,053 underlying) - Exercise/Conversion
Common Stock
2025-03-27$24.00/sh+26,606$638,544→ 603,682 total - Exercise/Conversion
Common Stock
2025-03-27$5.10/sh+32,193$164,184→ 757,541 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−16,666→ 0 totalExercise: $25.05Exp: 2029-01-24→ Common Stock (16,666 underlying) - Sale
Common Stock
2025-03-27$66.79/sh−23,095$1,542,552→ 715,084 total - Sale
Common Stock
2025-03-27$65.81/sh−106,471$7,007,059→ 994,414 total - Sale
Common Stock
2025-03-27$67.37/sh−8,423$567,458→ 776,302 total - Sale
Common Stock
2025-03-27$65.97/sh−14,183$935,640→ 738,179 total - Sale
Common Stock
2025-03-27$72.64/sh−732$53,172→ 577,076 total - Exercise/Conversion
Common Stock
2025-03-27$2.41/sh+62,291$150,121→ 819,832 total - Sale
Common Stock
2025-03-27$69.30/sh−199,226$13,805,904→ 577,076 total - Sale
Common Stock
2025-03-27$70.73/sh−3,291$232,786→ 582,590 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−32,193→ 8,473 totalExercise: $5.10Exp: 2032-01-28→ Common Stock (32,193 underlying) - Sale
Common Stock
2025-03-27$67.70/sh−41,989$2,842,685→ 673,095 total - Sale
Common Stock
2025-03-27$69.84/sh−31,980$2,233,390→ 585,881 total - Sale
Common Stock
2025-03-27$68.79/sh−55,234$3,799,442→ 617,861 total - Sale
Common Stock
2025-03-27$71.74/sh−4,782$343,076→ 577,808 total - Exercise/Conversion
Common Stock
2025-03-27$33.60/sh+105,000$3,528,000→ 725,348 total - Exercise/Conversion
Common Stock
2025-03-27$5.25/sh+281,053$1,475,528→ 1,100,885 total - Sale
Common Stock
2025-03-27$66.33/sh−209,689$13,908,797→ 784,725 total - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−26,606→ 60 totalExercise: $24.00Exp: 2028-02-07→ Common Stock (26,606 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-03-27−105,000→ 35,000 totalExercise: $33.60Exp: 2031-01-08→ Common Stock (105,000 underlying) - Exercise/Conversion
Common Stock
2025-03-27$25.05/sh+16,666$417,483→ 620,348 total
Footnotes (18)
- [F1]These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
- [F10]This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F11]This transaction was executed in multiple trades at prices ranging from $65.045 to $66.04. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F12]This transaction was executed in multiple trades at prices ranging from $66.045 to $66.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F13]This transaction was executed in multiple trades at prices ranging from $67.095 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F14]All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- [F15]Twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F16]One forty-eighth (1/48th) of the shares subject to the Option vested on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F17]One forty-eighth of the shares subject to the option vest on February 1, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.
- [F18]One thirty-sixth of the shares subject to the Option vest on June 26, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
- [F2]This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
- [F4]This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F6]This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F7]This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F8]This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F9]This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Documents
Issuer
SOLENO THERAPEUTICS INC
CIK 0001484565
Entity typeother
Related Parties
1- filerCIK 0001614821
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 7:00 PM ET
- Size
- 51.5 KB